Galecto Validates LOXL2 Targeting With Interim Myelofibrosis Phase II Success
Executive Summary
The US biotech’s LOXL2 inhibitor candidate has reduced collagen fibrosis of the bone marrow in a small number of Phase II patients, helping validate a historically tricky approach attempted by few.